Back

15 April 2024

April 2024 Gut Highlights

BSg-logo.png

Endoscopy

EUS-guided gallbladder drainage in acute cholecystitis

Bang J, Arnoletti J, Wagner A, et al. EUS-guided gallbladder drainage in acute cholecystitis: long-term problems with surgical approach. Gut 2024; 73: 395-397.  doi: 10.1136/gutjnl-2023-331245

Read it here.


Reducing scope 3 carbon emissions in gastrointestinal endoscopy: results of the prospective study of the ‘Green Endoscopy Project Würzburg’

Henniger D, Lux T, Windsheimer M, et al. Reducing scope 3 carbon emissions in gastrointestinal endoscopy: results of the prospective study of the ‘Green Endoscopy Project Würzburg’. Gut 2024; 73: 442-447. doi: 10.1136/gutjnl-2023-331024

Read it here.


Pancreas

Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis

Ammer-Herrmenau C, Antweiler K, Asendorf T, et al. Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis. Gut 2024; 73: 485-495. doi.org/10.1136/gutjnl-2023-330987.

Read it here.


Hepatology

Immunosuppressive CD29+ Treg accumulation in the liver in mice on checkpoint inhibitor therapy

Green B, Myojin Y, Ma C, et al.   Immunosuppressive CD29+ Treg accumulation in the liver in mice on checkpoint inhibitor therapy. Gut 2024; 73: 509-520. doi: 10.1136/gutjnl-2023-330024.

Read it here.


Oesophageal

Dupilumab demonstrated efficacy and tolerability in eosinophilic oesophagitis

Bredenoord A, Dellon E, Hirano I, et al. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study. Gut 2024; 73: 398-406. doi: 10.1136/gutjnl-2023-330220

Read it here.


IBD

Treatment of non-constipated irritable bowel syndrome with ebastine

Decraecker L, De Looze D, Hirsch D, et al. Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial. Gut 2024; 73: 459-469. doi: 10.1136/gutjnl-2023-331634

Read it here.

Reviewers

  • Dr Sam Withington, Internal Medicine Registrar 3 (IMT3), Kingston Hospital NHS Foundation Trust, Kingston Upon Thames, London, UK
  • Dr Catherine Hsu, Gastroenterology Registrar, Ealing Hospital, London North West University Healthcare NHS Trust, London, UK
  • Dr James Sun, Gastroenterology Registrar, St Mark’s Hospital and Academic Institute, London North West Healthcare NHS Trust, London, UK
  • Dr Khurum Hakeem, Gastroenterology Registrar, University Hospital of North Durham, Durham, UK
  • Dr Abisoye Akintimehin, Gastroenterology Registrar, Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK
  • Dr Kelly Chatten, Gastroenterology Registrar, North West Deanery, UK

BSG GUT Highlights is edited by Dr Philip J Smith, Honorary Consultant Luminal Gastroenterologist, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Mount Vernon, Liverpool, UK. Dr Smith is the Digital and Education Editor of GUT, Deputy Editor of Frontline Gastroenterology and Associate Editor of BMJ Open Gastroenterology.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Provenance and peer review

Not commissioned; internally peer reviewed.